U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control

number.							
	Substitute for	form 1449B	/PTO	Complete if Known			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/706.328		
				Filing Date	11/12/2003		
Date Submitted: December 19, 2006 (use as many sheets as necessary)				First Named Inventor	Alison Hannah, et al.		
				Group Art Unit	1614		
				Examiner Name	Amy A. Lewis		
Sheet	1	of	1	Attorney Docket Number	072121-0366 (19993.0005)		

				U.S. PATENT DOCUMENTS	5	
Examiner Initials*	Cite No.1	U.S. Patent Document			Date of Publication of	Pages, Columns, Lines,
		Number	Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appear
		4,659,657		Harnisch, et al.	4/21/1987	
		6,774,237		Renhowe, et al.	08/2004	

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No.1	Foreign Patent Document Office ³ Number ⁴ Kind Code ⁵ (If known)	Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶	
		HU P0104752	Aventis Pharmaceuticals	7/29/2002		-	
	-	WO 00/58315	LG Chemical Ltd.	10/05/2000		+	
		WO 01/12169	The Procter & Gamble Company	02/22/2001		1	
	L	WO 02/058697	Combinatorx Incorporated	08/01/2002			
		WO 02/26716	The Procter & Gamble Company	04/04/2002		 	
		WO 03/033472	Kirin Beer Kabashuiki Kaisha	04/24/2003			

	-	NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate itam (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issupublisher, city and/or country where published.		Т
		Grand, et al., "Targeting FGFR3 in Multiple Myeloma: Inhibition of t(4;14) Positive Cells by SU5402 and PD173074, Leukemia, 2004, Vol. 18, pp. 962-966.	T
		Dalton, et al., "Multiple Myeloma," Hematology, Am. Soc. Hematol. Educ. Program, 2001, 157-77,	+
		International Search Report for PCT/US04/36956 dated 10/2/2006.	+
			+

Examiner Signature	/James Anderson/	Date Considered	07/20/2010		
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to professed.					

considered. Include copy of this form with next communication to applicant.

1 Unique citation designation number. 2See attached Kinds of U.S. Patent Documents: 3Enter Office that issued the document, by the two-letter code (WIPO Standard STILL, the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible, "Applicant is to place a check mark here if English language."

Burden Hour Statement. This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandrie, VA 22313-1450. DO NOT SEND FEES OR CCMPLETED FORMS TO THIS ADDRESS. SEND TC: Commissioner for Patents, P.O. Box 1450, Alexandrie, VA 22313-1450. MADI_749430.1